Share this video  

ESMO 2018 | Cemiplimab prospects: CRC, CSCC & HNSCC

From the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Hani Babiker, MD, of the University of Arizona Cancer Center, Tucson, AZ, discusses the pathobiology of and prospects for selective inhibitors of nuclear export (SINE) in colorectal cancer, before discussing the results of the PD-1 checkpoint inhibitor, cemiplimab, for unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (NCT02383212). He then presents the exciting results from a Phase I trial of cemiplimab for metastatic head and neck squamous cell carcinoma (NCT02383212).